Indiana: Zantac (ranitidine) litigation | DrugsMonitor.com
Zantac (ranitidine) litigation in Indiana (IN): MDL-linked practice notes, filing deadline context, and a confidential attorney review—not legal advice.
NDMA, ranitidine, recalled heartburn medication, cancer allegations, Indiana
Readers in Indiana (IN) should know the federal MDL in Florida largely dismissed claims in 2022; this page summarizes historical themes only and is not a guide to current filings.
Procedural history
MDL No. 2924 centralized federal Zantac product liability cases. Daubert and preemption rulings significantly narrowed or ended many federal claims.
A small number of state-court paths may exist for limited scenarios; individualized legal research is required.
FAQ
What is Zantac / Ranitidine litigation about?
This page summarizes public litigation context and safety background for Zantac (ranitidine) litigation. It is educational—not a case evaluation for you personally.
Is this page legal advice?
No. DrugsMonitor.com is not a law firm. Nothing here tells you whether you have a claim or what you should do next legally.
How do I request a confidential review?
Use the intake or "Request a confidential review" options on this page. That may route you to a partner firm only when you choose to proceed.